US Stock Movement: Eli Lilly Surges on October 14th as Weekly Insulin is Approved and Receives Buy Rating

Lilly surges on October 14 — Analysis

Keywords: Weekly insulin approval, Buy rating

1. On October 13, the UK Medicines and Healthcare products Regulatory Agency approved Lilly's once-weekly insulin efsitora alfa Onswik for use in adults with type 2 diabetes. This long-acting basal insulin is administered once a week, which can reduce the number of annual injections for some patients from as many as 365 times to just 52 times.

2. On October 13, Citi maintained a Buy rating on Lilly, with a target price of $1,600. Barclays and BMO Capital Markets also maintained Buy ratings, both with a target price of $1,400.

(Disclaimer: This content is generated by AI technology summarizing public information, for reference only and does not constitute investment advice.)